TP53 and lymphoma: In contrast, mice transplanted with ATM- and p53-proficient lymphomas (JVM-2), or lymphomas with isolated p53 inactivation (HBL-2), did not derive a survival benefit from olaparib (Williamson et al., 2010, 2012).